6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
5 O
% O
) O
in O
the O
clinical O
trials O
were O
headache O
( O
18 O
% O
) O
, O
abdominal O
pain O
( O
12 O
% O
) O
, O
nausea O
( O
12 O
% O
) O
, O
dysmenorrhea O
( O
9 O
% O
) O
, O
fatigue O
( O
6 O
% O
) O
and O
dizziness O
( O
5 O
% O
) O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Afaxys O
, O
Inc O
. O
at O
1-855-888-2467 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

ella O
was O
studied O
in O
an O
open-label O
multicenter O
trial O
( O
Open-Label O
Study O
) O
and O
in O
a O
comparative O
, O
randomized O
, O
single-blind O
, O
multicenter O
trial O
( O
Single-Blind O
Comparative O
Study O
) O
. O

In O
these O
studies O
, O
a O
total O
of O
2,637 O
( O
1,533 O
+ O
1,104 O
) O
women O
in O
the O
30 O
mg O
ulipristal O
acetate O
groups O
were O
included O
in O
the O
safety O
analysis O
. O

The O
mean O
age O
of O
women O
who O
received O
ulipristal O
acetate O
was O
24.5 O
years O
and O
the O
mean O
body O
mass O
index O
( O
BMI O
) O
was O
25.3 O
. O

The O
racial O
demographics O
of O
those O
enrolled O
were O
67 O
% O
Caucasian O
, O
20 O
% O
Black O
or O
African O
American O
, O
2 O
% O
Asian O
, O
and O
12 O
% O
other O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
in O
the O
clinical O
trials O
for O
women O
receiving O
ella O
were O
headache B-OSE_Labeled_AE
( O
18 O
% O
overall O
) O
and O
nausea B-OSE_Labeled_AE
( O
12 O
% O
overall O
) O
and O
abdominal B-OSE_Labeled_AE
and O
upper O
abdominal O
pain I-OSE_Labeled_AE
( O
12 O
% O
overall O
) O
. O

Table O
1 O
lists O
those O
adverse O
reactions O
that O
were O
reported O
in O
> O
= O
5 O
% O
of O
subjects O
in O
the O
clinical O
studies O
( O
14 O
) O
. O

Table O
1 O
: O
Adverse O
Reactions O
in O
> O
= O
5 O
% O
of O
Women O
( O
% O
) O
Receiving O
a O
Single O
Dose O
of O
ella O
( O
30 O
mg O
Ulipristal O
Acetate O
) O
Most O
Common O
Adverse O
Reactions O
Open-Label O
Study O
Single-Blind O
Comparative O
Study O
N O
= O
1,533 O
N O
= O
1,104 O
Headache B-OSE_Labeled_AE
18 O
19 O
Nausea B-OSE_Labeled_AE
12 O
13 O
Abdominal B-OSE_Labeled_AE
and O
upper O
abdominal O
pain I-OSE_Labeled_AE
15 O
8 O
Dysmenorrhea B-OSE_Labeled_AE
7 O
13 O
Fatigue B-OSE_Labeled_AE
6 O
6 O
Dizziness B-OSE_Labeled_AE
5 O
5 O
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
ella O
: O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Acne B-OSE_Labeled_AE
Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

